摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-fluoro-5-(3'-pyridyl)phenylamine | 181633-36-3

中文名称
——
中文别名
——
英文名称
3-fluoro-5-(3'-pyridyl)phenylamine
英文别名
3-fluoro-5-(pyridin-3-yl)aniline;3-fluoro-5-(3-pyridyl)aniline;Benzenamine, 3-fluoro-5-(3-pyridinyl)-;3-fluoro-5-pyridin-3-ylaniline
3-fluoro-5-(3'-pyridyl)phenylamine化学式
CAS
181633-36-3
化学式
C11H9FN2
mdl
——
分子量
188.204
InChiKey
NFIXYAVTGLYDLV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    371.8±32.0 °C(Predicted)
  • 密度:
    1.218±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    38.9
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    유기발광 화합물 및 이를 포함하는 유기전계발광소자
    摘要:
    This invention is an organic light-emitting compound represented by the following chemical formula 1, characterized by its asymmetric structure with respect to L---L', in which high efficiency or long-lasting characteristics can be achieved by respectively combining substituents with pyrene compounds in an asymmetric manner to have excellent luminous efficiency and lifespan characteristics, as well as excellent color purity and thermal stability. Organic light-emitting devices containing this compound have excellent luminous characteristics such as color purity, luminous efficiency, and long lifespan, making them suitable for various display devices. [Chemical formula 1]
    公开号:
    KR20150129486A
  • 作为产物:
    描述:
    1-氟-3-碘-5-硝基苯盐酸四(三苯基膦)钯 、 sodium carbonate 、 tin(ll) chloride 作用下, 以 乙二醇二甲醚 为溶剂, 反应 12.0h, 生成 3-fluoro-5-(3'-pyridyl)phenylamine
    参考文献:
    名称:
    Biarylcarbamoylindolines Are Novel and Selective 5-HT2C Receptor Inverse Agonists:  Identification of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a Potential Antidepressant/Anxiolytic Agent
    摘要:
    The evolution, synthesis, and biological activity of a novel series of 5-HT2C receptor inverse agonists are reported. Biarylcarbamoylindolines have been identified with excellent 5-HT2C affinity and selectivity over 5-HT2A receptors. In addition, (pyridyloxypyridyl)carbamoylindolines have been discovered with additional selectivity over the closely related 5-HT2B receptor. Compounds from this series are inverse agonists at the human cloned 5-HT2C receptor, completely abolishing basal activity in a functional assay. The new series have reduced P450 inhibitory liability compared to a previously described series of 1-(3-pyridylcarbamoyl)indolines (Bromidge et al. J. Med. Chem. 1998, 41, 1598) from which they evolved. Compounds from this series showed excellent oral activity in a rat mCPP hypolocomotion model and in animal models of anxiety. On the basis of their favorable biological profile, 32 (SB-228357) and 40 (SB-243213) have been selected for further evaluation to determine their therapeutic potential for the treatment of CNS disorders such as depression and anxiety.
    DOI:
    10.1021/jm990388c
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS<br/>[FR] ANALOGUES D'URÉE PONTÉS SUBSTITUÉS EN TANT QUE MODULATEURS DE SIRTUINE
    申请人:GLAXOSMITHKLINE IP NO 2 LTD
    公开号:WO2016079709A1
    公开(公告)日:2016-05-26
    The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
    本发明涉及一种新型的取代桥式脲类似物化合物,其化学式为(I)或其药学上可接受的盐,相应的药物组合物,制备这种化合物的方法以及单独使用或与其他治疗剂联合使用的这些化合物作为Sirtuin调节剂,可用于增加细胞寿命,并用于治疗和/或预防各种疾病和紊乱,包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症和/或潮红有关的疾病或紊乱,以及那些会受益于增加线粒体活性的疾病或紊乱。
  • A P,N-Ligand for Palladium-Catalyzed Ammonia Arylation: Coupling of Deactivated Aryl Chlorides, Chemoselective Arylations, and Room Temperature Reactions
    作者:Rylan J. Lundgren、Brendan D. Peters、Pamela G. Alsabeh、Mark Stradiotto
    DOI:10.1002/anie.201000526
    日期:2010.6.1
    Amazing ammonia: A new air‐stable P,Nligand (Mor‐DalPhos) is reported that enables the palladium‐catalyzed cross‐coupling of ammonia to a variety of aryl chloride and aryl tosylate substrates with high chemoselectivity and, for the first time, at room temperature (see scheme; Ad=adamantyl, Ts=para‐toluenesulfonyl).
    惊人的氨气:据报道,一种新型的空气稳定的P,N-配体(Mor-DalPhos)使钯催化的氨气与多种具有高化学选择性的芳基氯和甲苯磺酸芳基酯的交叉偶联成为首次。 ,在室温下(参见方案; Ad =金刚烷基,Ts =对甲苯磺酰基)。
  • [EN] INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST<br/>[FR] DERIVES D'INDOLE UTILISES COMME ANTAGONISTE DU RECEPTEUR DE 5-HT
    申请人:SMITHKLINE BEECHAM PLC
    公开号:WO1996023783A1
    公开(公告)日:1996-08-08
    (EN) The invention relates to heterocyclic compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders such as anxiety.(FR) L'invention concerne des composés hétérocycliques présentant une activité pharmacologique, leurs procédés de préparation, des compositions les contenant ainsi que leur utilisation dans le traitement de troubles du système nerveux central tels que l'anxiété.
    该发明涉及具有药理活性的杂环化合物,其制备过程,包含它们的组成物以及它们在治疗中枢神经系统障碍,如焦虑症方面的应用。
  • Indole derivatives as 5-HT receptor antagonist
    申请人:SmithKline Beecham p.l.c.
    公开号:US20030105139A1
    公开(公告)日:2003-06-05
    The invention relates to heterocyclic compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders such as anxiety.
    本发明涉及具有药理活性的杂环化合物,其制备过程,含有它们的组合物以及它们在治疗中枢神经系统疾病如焦虑症方面的应用。
  • Quinoline derivatives as phosphodiesterase inhibitors
    申请人:Barker David Michael
    公开号:US20060178416A1
    公开(公告)日:2006-08-10
    There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
    根据本发明提供了公式(I)的新化合物或其药学上可接受的盐,其中R1、R2、R19、R20和R34如规范所述,以及制备它们的过程、包含它们的制剂和它们在治疗炎症性疾病方面的用途。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-